A Phase 2 Study of Zilovertamab Vedotin With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab (R-CHP) in Diffuse Large B-Cell Lymphoma: waveLINE-007

被引：0
|
作者：
David, Lavie [1 ]
Muhit, Ozcan [2 ]
Ewa, Paszkiewicz-Kozik [3 ]
Eva, Gonzalez Barca [4 ]
Min, Kim Tae [5 ]
Benedetta, Puccini [6 ]
Siruo, Wang [7 ]
Rushdia, Yusuf [7 ]
Patricia, Marinello [7 ]
Seog, Kim Won [8 ]
机构：
[1] Hadassah Med Ctr, Jerusalem, Israel
[2] Ankara Univ, Sch Med, Ankara, Turkiye
[3] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[4] Barcelona Univ, IDIBELL, Inst Catala Oncol Hosp, Barcelona, Spain
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Azienda Osped Univ Careggi, Florence, Italy
[7] Merck & Co Inc, Rahway, NJ USA
[8] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-050
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [31] Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
    Forero-Torres, Andres
    Kolibaba, Kathryn S.
    Tilly, Herve
    Salles, Gilles
    Wang, Lijia
    Lee, Calvin
    Sharman, Jeffrey P.
    BLOOD, 2017, 130
  • [32] Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma
    Wöhrer, S
    Püspök, A
    Drach, J
    Hejna, M
    Chott, A
    Raderer, M
    ANNALS OF ONCOLOGY, 2004, 15 (07) : 1086 - 1090
  • [33] Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study
    Zhao, Peiqi
    Zhao, Shu
    Huang, Chen
    Li, Yajun
    Wang, Jiesong
    Xu, Junqing
    Li, Lanfang
    Qian, Zhengzi
    Li, Wei
    Zhou, Shiyong
    Qiu, Lihua
    Liu, Xianming
    Chen, Ying
    Jiang, Yanan
    Zheng, Yanbin
    Chen, Daoguang
    Zhou, Hui
    Gao, Yuhuan
    Zhang, Qingyuan
    Zhang, Huilai
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
  • [34] Epidemiological impact of Polatuzumab vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) use in previously untreated Diffuse Large B-cell Lymphoma (DLBCL) on Second Line (2L) treatment: an ad hoc analysis from POLARIX study
    Oellerich, T.
    Boissard, F.
    Tilly, H.
    Lenz, G.
    Collins, G. P.
    Pinto, A.
    Sehn, L. H.
    Salles, G.
    Roussel, M.
    Simonella, L.
    Ho, R.
    Hirata, J.
    Lee, C.
    Masaquel, A.
    Launonen, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 267 - 267
  • [35] Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma
    Steiner, Raphael E.
    Strati, Paolo
    Flowers, Christopher R.
    Neelapu, Sattva S.
    Green, Michael R.
    Nastoupil, Loretta
    Hagemeister, Fredrick B.
    Feng, Lei
    Ahmed, Sairah
    Nair, Ranjit
    Fayad, Luis
    Lee, Hun Ju
    Rodriguez, Maria Alma
    Westin, Jason R.
    BLOOD, 2021, 138
  • [36] Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone
    Hui, David
    Proctor, Bradley
    Donaldson, Jane
    Shenkier, Tamara
    Hoskins, Paul
    Klasa, Richard
    Savage, Kerry
    Chhanabhai, Mukesh
    Gascoyne, Randy D.
    Connors, Joseph M.
    Sehn, Laurie H.
    LEUKEMIA & LYMPHOMA, 2010, 51 (09) : 1658 - 1667
  • [37] Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi
    Chiappella, Annalisa
    Tucci, Alessandra
    Castellino, Alessia
    Pavone, Vincenzo
    Baldi, Ileana
    Carella, Angelo Michele
    Orsucci, Lorella
    Zanni, Manuela
    Salvi, Flavia
    Liberati, Anna Marina
    Gaidano, Gianluca
    Bottelli, Chiara
    Rossini, Bernardo
    Perticone, Sonia
    De Masi, Pasqualina
    Ladetto, Marco
    Ciccone, Giovannino
    Palumbo, Antonio
    Rossi, Giuseppe
    Vitolo, Umberto
    HAEMATOLOGICA, 2013, 98 (11) : 1732 - 1738
  • [38] The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma
    Kawasaki, Natsumi
    Nishito, Yukari
    Yoshimura, Yasushi
    Yoshiura, Shigeki
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 245 - 255
  • [39] Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
    Lugtenburg, Pieternella
    Avivi, Irit
    Berenschot, Henriette
    Ilhan, Osman
    Marolleau, Jean Pierre
    Nagler, Arnon
    Rueda, Antonio
    Tani, Monica
    Turgut, Mehmet
    Osborne, Stuart
    Smith, Rodney
    Pfreundschuh, Michael
    HAEMATOLOGICA, 2017, 102 (11) : 1913 - 1922
  • [40] Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study
    Boissard, Frederic
    Tilly, Herve
    Lenz, Georg
    Collins, Graham P.
    Pinto, Antonio
    Sehn, Laurie H.
    Salles, Gilles
    Roussel, Mathilde
    Simonella, Leonardo
    Ho, Rodrigo
    Hirata, Jamie
    Lee, Calvin
    Masaquel, Anthony
    Launonen, Aino
    BLOOD, 2022, 140 : 6645 - 6647
12345